DG
TRIL

David Goel’s Trillium Therapeutics Inc. TRIL Stock Holding History

David Goel’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,288,560
Closed -$704K – 25
2019
Q3 		$704K Hold
2,288,560
– – 0.02% 23
2019
Q2 		$753K Hold
2,288,560
– – 0.01% 24
2019
Q1 		$1.51M Hold
2,288,560
– – 0.04% 20
2018
Q4 		$3.91M Hold
2,288,560
– – 0.13% 19
2018
Q3 		$13.3M Hold
2,288,560
– – 0.33% 21
2018
Q2 		$13.7M Buy
2,288,560
+36,554
+2% +$233K 0.39% 20
2018
Q1 		$16.2M Buy
2,252,006
+79,006
+4% +$599K 0.56% 21
2017
Q4 		$15.8M Buy
+2,173,000
New +$18M 0.56% 18

Other funds holding TRIL

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

David Goel's TRIL Position: Q4 2019 in Review

David Goel sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2019, closing a stake of 2,288,560 shares — an estimated $704K sold.

David Goel first reported a position in TRIL in Q4 2017 and held it in 8 quarters. The position peaked at $16.2M in Q1 2018. 19 funds tracked by Wall St. Rank hold TRIL as of Q4 2019.

  • David Goel reported no remaining Trillium Therapeutics Inc. position as of Q4 2019 after selling out during the quarter.
  • David Goel sold 2,288,560 Trillium Therapeutics Inc. shares in Q4 2019, an estimated $704K.
  • David Goel first reported a position in Trillium Therapeutics Inc. in Q4 2017 and held it in 8 quarters.
  • David Goel's Trillium Therapeutics Inc. position peaked at $16.2M in Q1 2018.
  • 19 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2019.

Based on Matrix Capital Management Company's 13F filing for Q4 2019, filed 14 Feb 2020.